Best Medical International Celebrated 50 Years
The radiation therapy company reached a half-century milestone in 2026.
Updated on Oct. 6, 2026 in Stroke
Best Medical International marked its 50th anniversary in 2026, a milestone reached nearly six decades after the founder lost his father to colon cancer. The company continues to develop radiation therapy technologies used in clinical settings.
Why it matters
The company's history reflects the evolving landscape of radiation technology, which has significantly advanced since the founder first sought to improve cancer care. Its ongoing development of radiotherapy tools aims to expand global access to diagnostic and therapeutic options.
The company established its history through early animal studies for vascular brachytherapy 35 years ago, leading to FDA approval for in-stent coronary artery restenosis in 2000. These early findings paved the way for current cyclotron technology ranges of 7.5 MeV to 230 MeV.
The players
Best Medical International
A Washington-based developer of radiation therapy systems and medical technology.
Dr. Krishnan Suthanthiran
The founder of Best Medical International who established the company following the loss of his father.
The details
Best Medical International specializes in the development and acquisition of radiation therapy technologies, including high-current proton cyclotrons. These devices function by accelerating protons to high energies, enabling targeted radiation delivery for various medical applications. The company recently completed factory acceptance testing for a 70-MeV cyclotron before shipping it to the National Atomic Research Institute in Taipei.
Timeline
The founder lost his father to colon cancer in 1968.
The company began vascular brachytherapy animal studies 35 years ago.
The U.S. FDA approved vascular brachytherapy for in-stent coronary artery restenosis in 2000.
Best Medical International marked its 50th anniversary in 2026.
Health Landscape
The shipment of the cyclotron to the National Atomic Research Institute marks a significant expansion in regional proton therapy infrastructure. This development follows the established pattern of international collaboration between medical technology firms and research centers to advance radiotherapy.
While this milestone highlights long-term industry progress, specific treatment decisions regarding radiation therapy should always be discussed with your physician. Understanding the available options for targeted care is a vital step when reviewing potential cancer treatment plans.
The takeaway
The company's 50-year legacy highlights the importance of continuous innovation in medical physics. Patients undergoing radiation treatment should maintain open communication with their oncology team to understand the most current technological options available for their specific care needs.
Further reading
For more on the latest research and clinical standards, visit our Stroke section.
